$ALDX
Aldeyra Therapeutics, Inc.

2023 Q2 Form 10-Q Financial Statement

#000095017023017827 Filed on May 04, 2023

View on sec.gov

Income Statement

Concept 2023 Q2 2023 Q1 2022 Q1
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $3.380M $5.567M $4.249M
YoY Change 7.49% 31.02% 37.08%
% of Gross Profit
Research & Development $6.963M $11.24M $12.23M
YoY Change -52.21% -8.16% 58.35%
% of Gross Profit
Depreciation & Amortization $64.34K $66.97K $62.74K
YoY Change 0.52% 6.74% -7.55%
% of Gross Profit
Operating Expenses $10.34M $11.24M $12.23M
YoY Change -29.02% -8.16% 58.35%
Operating Profit -$10.34M -$16.80M -$16.48M
YoY Change -41.62% 1.94% 52.19%
Interest Expense $1.356M $491.3K $406.0K
YoY Change 230.33% 21.02% -15.88%
% of Operating Profit
Other Income/Expense, Net $1.356M $1.188M -$304.6K
YoY Change -2153.5% -489.91% -33.62%
Pretax Income -$8.987M -$15.62M -$16.79M
YoY Change -49.46% -6.98% 48.7%
Income Tax
% Of Pretax Income
Net Earnings -$8.987M -$15.62M -$16.79M
YoY Change -49.46% -6.98% 48.7%
Net Earnings / Revenue
Basic Earnings Per Share -$0.15 -$0.27 -$0.29
Diluted Earnings Per Share -$0.15 $0.27 -$288.0K
COMMON SHARES
Basic Shares Outstanding 58.58M 58.58M 58.10M
Diluted Shares Outstanding 58.79M 58.79M 58.30M

Balance Sheet

Concept 2023 Q2 2023 Q1 2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $151.7M $165.0M $216.9M
YoY Change -22.89% -23.9% 56.65%
Cash & Equivalents $40.17M $165.0M $158.9M
Short-Term Investments $0.00 $0.00 $57.96M
Other Short-Term Assets $3.804M $23.69K $5.489M
YoY Change -6.14% -99.57% -36.18%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $155.5M $168.0M $222.4M
YoY Change -22.55% -24.44% 51.19%
LONG-TERM ASSETS
Property, Plant & Equipment $137.2K $12.54K $41.42K
YoY Change 303.13% -69.73% -28.04%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $137.2K $201.6K $337.9K
YoY Change -49.9% -40.35% 44.92%
TOTAL ASSETS
Total Short-Term Assets $155.5M $168.0M $222.4M
Total Long-Term Assets $137.2K $201.6K $337.9K
Total Assets $155.6M $168.2M $222.7M
YoY Change -22.58% -24.46% 51.18%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $270.8K $429.7K $2.443M
YoY Change 2.5% -82.41% 444.56%
Accrued Expenses $9.440M $14.43M $13.68M
YoY Change -12.67% 5.54% 154.59%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $5.894M $954.3K $0.00
YoY Change 19.66% -100.0%
Total Short-Term Liabilities $15.61M $16.01M $16.35M
YoY Change -3.93% -2.12% 47.34%
LONG-TERM LIABILITIES
Long-Term Debt $10.13M $14.97M $15.59M
YoY Change -5.73% -3.97% 53.7%
Other Long-Term Liabilities $63.33K
YoY Change
Total Long-Term Liabilities $10.13M $14.97M $15.59M
YoY Change -5.73% -3.97% 53.7%
TOTAL LIABILITIES
Total Short-Term Liabilities $15.61M $16.01M $16.35M
Total Long-Term Liabilities $10.13M $14.97M $15.59M
Total Liabilities $25.73M $30.98M $32.00M
YoY Change -4.64% -3.21% 50.96%
SHAREHOLDERS EQUITY
Retained Earnings -$381.3M -$372.3M -$311.5M
YoY Change 15.81% 19.54% 25.49%
Common Stock $511.2M $509.6M $502.2M
YoY Change 1.51% 1.46%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $129.9M $137.2M $190.7M
YoY Change
Total Liabilities & Shareholders Equity $155.6M $168.2M $222.7M
YoY Change -22.58% -24.46% 51.18%

Cashflow Statement

Concept 2023 Q2 2023 Q1 2022 Q1
OPERATING ACTIVITIES
Net Income -$8.987M -$15.62M -$16.79M
YoY Change -49.46% -6.98% 48.7%
Depreciation, Depletion And Amortization $64.34K $66.97K $62.74K
YoY Change 0.52% 6.74% -7.55%
Cash From Operating Activities -$13.36M -$9.444M -$12.87M
YoY Change -33.07% -26.64% -4.44%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $0.00 $16.32K
YoY Change -100.0% 109.03%
Acquisitions
YoY Change
Other Investing Activities $0.00 $30.00M -$58.02M
YoY Change -100.0% -151.71%
Cash From Investing Activities $0.00 $30.00M -$58.03M
YoY Change -100.0% -151.7% 743325.39%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $0.00
YoY Change -100.0%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 5.290K 52.56K 23.32K
YoY Change 125.34% -99.97%
NET CHANGE
Cash From Operating Activities -13.36M -9.444M -12.87M
Cash From Investing Activities 0.000 30.00M -58.03M
Cash From Financing Activities 5.290K 52.56K 23.32K
Net Change In Cash -13.35M 20.61M -70.88M
YoY Change -64.77% -129.07% -217.0%
FREE CASH FLOW
Cash From Operating Activities -$13.36M -$9.444M -$12.87M
Capital Expenditures $0.00 $0.00 $16.32K
Free Cash Flow -$13.36M -$9.444M -$12.89M
YoY Change -33.07% -26.73% -4.38%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001341235
CY2023Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023Q1 dei Amendment Flag
AmendmentFlag
false
CY2023Q1 dei Document Type
DocumentType
10-Q
CY2023Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2023Q1 dei Document Period End Date
DocumentPeriodEndDate
2023-03-31
CY2023Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2023Q1 dei Entity File Number
EntityFileNumber
001-36332
CY2023Q1 dei Entity Registrant Name
EntityRegistrantName
ALDEYRA THERAPEUTICS, INC.
CY2023Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2023Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
20-1968197
CY2023Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
131 Hartwell Avenue
CY2023Q1 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 320
CY2023Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2023Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2023Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2023Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Lexington
CY2023Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
CY2023Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02421
CY2023Q1 dei City Area Code
CityAreaCode
781
CY2023Q1 dei Local Phone Number
LocalPhoneNumber
761-4904
CY2023Q1 dei Security12b Title
Security12bTitle
Common Stock, $0.001 par value per share
CY2023Q1 dei Trading Symbol
TradingSymbol
ALDX
CY2023Q1 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2023Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
58560078
CY2023Q1 dei Entity Shell Company
EntityShellCompany
false
CY2023Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
58576350
CY2023Q1 aldx Cash And Money Market Funds
CashAndMoneyMarketFunds
165028105
CY2022Q4 aldx Cash And Money Market Funds
CashAndMoneyMarketFunds
144419364
CY2023Q1 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
0
CY2022Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
29881520
CY2023Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2989115
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
6722229
CY2023Q1 us-gaap Assets Current
AssetsCurrent
168017220
CY2022Q4 us-gaap Assets Current
AssetsCurrent
181023113
CY2023Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
189033
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
249265
CY2023Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
12539
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
19279
CY2023Q1 us-gaap Assets
Assets
168218792
CY2022Q4 us-gaap Assets
Assets
181291657
CY2023Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
429685
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
133625
CY2023Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
14433679
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
14065885
CY2023Q1 us-gaap Long Term Debt Current
LongTermDebtCurrent
954325
CY2022Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
911763
CY2023Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
190202
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
249265
CY2023Q1 us-gaap Liabilities Current
LiabilitiesCurrent
16007891
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
15360538
CY2023Q1 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
14967688
CY2022Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
14923090
CY2023Q1 us-gaap Liabilities
Liabilities
30975579
CY2022Q4 us-gaap Liabilities
Liabilities
30283628
CY2023Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
15000000
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
15000000
CY2023Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q1 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2023Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2023Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
58791603
CY2023Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
58791603
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
58560078
CY2023Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
103938
CY2023Q1 us-gaap Common Stock Value
CommonStockValue
58792
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
58560
CY2023Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
509516738
CY2022Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
507770045
CY2023Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
0
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-103938
CY2023Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-372332317
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-356716638
CY2023Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
137243213
CY2022Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
151008029
CY2023Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
168218792
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
181291657
CY2023Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
11235861
CY2022Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
12234320
CY2023Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5567416
CY2022Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4249387
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-16803277
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-16483707
CY2023Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
1678885
CY2022Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
101382
CY2023Q1 us-gaap Interest Expense
InterestExpense
491287
CY2022Q1 us-gaap Interest Expense
InterestExpense
405967
CY2023Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1187598
CY2022Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-304585
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-15615679
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-16788292
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.27
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.27
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.29
CY2022Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.29
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
58791603
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
58791603
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
58297861
CY2022Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
58297861
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-15615679
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-16788292
CY2023Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
103938
CY2022Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-61677
CY2023Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
103938
CY2022Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-61677
CY2023Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-15511741
CY2022Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-16849969
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
151008029
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1694366
CY2023Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
52559
CY2023Q1 us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
0
CY2023Q1 aldx Net Loss
NetLoss
-15615679
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
137243213
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
205735523
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1779844
CY2022Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
23324
CY2022Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
0
CY2022Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-61677
CY2022Q1 aldx Net Loss
NetLoss
-16788292
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
190688722
CY2023Q1 us-gaap Profit Loss
ProfitLoss
-15615679
CY2022Q1 us-gaap Profit Loss
ProfitLoss
-16788292
CY2023Q1 us-gaap Share Based Compensation
ShareBasedCompensation
4190356
CY2022Q1 us-gaap Share Based Compensation
ShareBasedCompensation
1936578
CY2023Q1 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
87160
CY2022Q1 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
82798
CY2023Q1 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
14542
CY2022Q1 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
3228
CY2023Q1 us-gaap Depreciation
Depreciation
66972
CY2022Q1 us-gaap Depreciation
Depreciation
62741
CY2023Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-3733114
CY2022Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
2526926
CY2023Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
296060
CY2022Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1423128
CY2023Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-2187259
CY2022Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
2940002
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-9443818
CY2022Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-12873199
CY2023Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
0
CY2022Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
16317
CY2023Q1 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
0
CY2022Q1 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
58015469
CY2023Q1 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
30000000
CY2022Q1 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
0
CY2023Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
30000000
CY2022Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-58031786
CY2023Q1 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
52559
CY2022Q1 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
23324
CY2023Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
52559
CY2022Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
23324
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
20608741
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-70881661
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
144419364
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
229790989
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
165028105
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
158909328
CY2023Q1 us-gaap Interest Paid Net
InterestPaidNet
397396
CY2022Q1 us-gaap Interest Paid Net
InterestPaidNet
322500
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
6722229
CY2023Q1 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
14967688
CY2022Q4 us-gaap Deferred Tax Liabilities Deferred Expense Capitalized Research And Development Costs
DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts
2605252
CY2023Q1 us-gaap Prepaid Insurance
PrepaidInsurance
152860
CY2022Q4 us-gaap Prepaid Insurance
PrepaidInsurance
432230
CY2023Q1 us-gaap Other Assets Current
OtherAssetsCurrent
23685
CY2022Q4 us-gaap Other Assets Current
OtherAssetsCurrent
3242026
CY2023Q1 us-gaap Other Assets Miscellaneous Current
OtherAssetsMiscellaneousCurrent
272802
CY2023Q1 us-gaap Nature Of Operations
NatureOfOperations
<div style="text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">1.</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">NATURE OF BUSINESS </span></div></div><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Aldeyra Therapeutics, Inc., together with its wholly-owned subsidiaries (the “Company” or “Aldeyra”), a Delaware corporation, is a clinical-stage biotechnology company devoted to discovering innovative therapies designed to treat immune-mediated diseases.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company’s principal activities to date include research and development activities along with related general business planning, including raising capital.</span></p>
CY2023Q1 us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Use of Estimates</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The preparation of condensed consolidated financial statements in conformity with US GAAP requires management to make estimates and assumptions, including fair value estimates for investments that affect the reported amounts of assets and liabilities, and the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements, and the reported amounts of expenses during the reporting periods. The Company’s management evaluates its estimates and assumptions on an ongoing basis. Management’s most significant estimates in the Company’s condensed consolidated financial statements include, but are not limited to, clinical trial accruals, deferred and accrued research and development costs, stock-based compensation, and accounting for income taxes and related valuation allowance. Although these estimates and assumptions are based on the Company’s knowledge of current events and actions it may undertake in the future, actual results may ultimately materially differ from these estimates and assumptions.</span>
CY2022Q4 us-gaap Other Assets Miscellaneous Current
OtherAssetsMiscellaneousCurrent
442721
CY2023Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2989115
CY2023Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7640146
CY2022Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6679372
CY2023Q1 us-gaap Marketable Securities
MarketableSecurities
0
CY2022Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
29985458
CY2022 us-gaap Available For Sale Debt Securities Gross Unrealized Loss
AvailableForSaleDebtSecuritiesGrossUnrealizedLoss
103938
CY2022Q4 us-gaap Debt Instrument Fair Value
DebtInstrumentFairValue
29881520
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
144419364
CY2022Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
29881520
CY2023Q1 us-gaap Liabilities Fair Value Disclosure
LiabilitiesFairValueDisclosure
0
CY2022Q4 us-gaap Liabilities Fair Value Disclosure
LiabilitiesFairValueDisclosure
0
CY2023Q1 us-gaap Deferred Tax Liabilities Deferred Expense Capitalized Research And Development Costs
DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts
2539768
CY2023Q1 us-gaap Lines Of Credit Current
LinesOfCreditCurrent
954325
CY2022Q4 us-gaap Lines Of Credit Current
LinesOfCreditCurrent
911763
CY2023Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
5510667
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
3821904
CY2023Q1 aldx Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
6360103
CY2022Q4 aldx Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
8476422
CY2023Q1 us-gaap Other Accrued Liabilities Current And Noncurrent
OtherAccruedLiabilitiesCurrentAndNoncurrent
2562909
CY2022Q4 us-gaap Other Accrued Liabilities Current And Noncurrent
OtherAccruedLiabilitiesCurrentAndNoncurrent
1767559
CY2023Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
14433679
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
14065885
CY2023Q1 us-gaap Long Term Loans Payable
LongTermLoansPayable
15000000
CY2022Q4 us-gaap Long Term Loans Payable
LongTermLoansPayable
15000000
CY2023Q1 aldx End Of Term Charge
EndOfTermCharge
974886
CY2022Q4 aldx End Of Term Charge
EndOfTermCharge
911763
CY2023Q1 us-gaap Unamortized Debt Issuance Expense
UnamortizedDebtIssuanceExpense
52873
CY2022Q4 us-gaap Unamortized Debt Issuance Expense
UnamortizedDebtIssuanceExpense
76910
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
3771769
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
6.12
CY2022Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
14923090
CY2022Q4 us-gaap Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year
LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear
1042500
CY2022Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
15292500
CY2022Q4 us-gaap Long Term Debt
LongTermDebt
16335000
CY2023Q1 aldx Deferred Tax Assets Valuation Allowance Percentage
DeferredTaxAssetsValuationAllowancePercentage
1
CY2019 aldx Share Based Compensation Arrangement By Share Based Payment Award Granted Period1
ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantedPeriod1
P4Y
CY2020 aldx Share Based Compensation Arrangement By Share Based Payment Award Granted Period1
ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantedPeriod1
P4Y
CY2022 aldx Share Based Compensation Arrangement By Share Based Payment Award Granted Period1
ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantedPeriod1
P4Y
CY2023Q1 us-gaap Employee Benefits And Share Based Compensation
EmployeeBenefitsAndShareBasedCompensation
2600000
CY2023Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4190356
CY2022Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1936578
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5403982
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
5.90
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y6M21D
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
10506953
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1028064
CY2023Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
6.76
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
6432046
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
6.04
CY2023Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y10M17D
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
26374880
CY2023Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P5Y3M18D
CY2023Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
15217207
CY2023Q1 us-gaap Share Price
SharePrice
9.93
CY2023Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
200000
CY2023Q1 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.091
CY2023Q1 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P0Y9M
CY2023Q1 us-gaap Operating Lease Expense
OperatingLeaseExpense
65500
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
197540
CY2023Q1 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
7338
CY2023Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
190202
CY2023Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
190202
CY2023Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
190202
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
197540
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
197540
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
0
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
0
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
0
CY2023Q1 aldx Indemnification Obligations Claims Outstanding
IndemnificationObligationsClaimsOutstanding
0
CY2023Q1 aldx Cash Reserve For Indemnities And Guarantees
CashReserveForIndemnitiesAndGuarantees
0

Files In Submission

Name View Source Status
aldx-20230331_cal.xml Edgar Link unprocessable
0000950170-23-017827-index-headers.html Edgar Link pending
0000950170-23-017827-index.html Edgar Link pending
0000950170-23-017827.txt Edgar Link pending
0000950170-23-017827-xbrl.zip Edgar Link pending
aldx-20230331.htm Edgar Link pending
aldx-20230331.xsd Edgar Link pending
aldx-ex31_1.htm Edgar Link pending
aldx-ex31_2.htm Edgar Link pending
aldx-ex32_1.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
aldx-20230331_lab.xml Edgar Link unprocessable
aldx-20230331_def.xml Edgar Link unprocessable
aldx-20230331_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
aldx-20230331_htm.xml Edgar Link completed
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending